Analysis of CEA Expression Level and EGFR Mutation Status in Non-small Cell Lung Cancer

Epidemiological data suggest that the incidence of non-small cell lung cancer (NSCLC) is rapidly rising, and smoking is the leading cause of lung cancer in the world. The traditional therapies for NSCLC mainly include surgery, radiotherapy, chemotherapy etc (Liu et al., 2013; Lu et al., 2013; Yan et al., 2013; Ji et al., 2014; Cui et al., 2014). However, these therapeutic interventions often bring about strong adverse reactions. Thus, molecular targeted therapy versus specific targeted sites has become a research hotspot in recent years. Epidermal growth factor receptor (EGFR) is a type of receptor tyrosine kinase, and it has been reported that EGFR mutations are mainly concentrated in exons 19 and 21 (Ji et al., 2006; Lim et al., 2014; Liam et al, 2014). After epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment, the signaling through